Use of tazarotene foam for the treatment of acne vulgaris.

ABSTRACT: Acne vulgaris is a common inflammatory chronic disease of the pilosebaceous unit. It often requires long-term treatment, resulting in increased demand for topical medications that are popular with patients in order to achieve long-term compliance. Tazarotene foam 0.1% is a novel formulation of tazarotene. We review efficacy and tolerability studies of the new formulation, and suggest a possible place for the product in the management of acne vulgaris.

SUBMITTER: Gregoriou S 

PROVIDER: S-EPMC4043801 | biostudies-other | 2014

REPOSITORIES: biostudies-other